Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 16/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1337815 | 0.93 | ALDH1A1 (0.48) | PTGESHDAC6EGFRRAF1BRAF | |
| SCHEMBL13393761 | 0.92 | PTGES (0.50) | PTGESCYP2D6 | |
| SCHEMBL1338240 | 0.92 | PTGES (0.51) | PTGESCYP2D6RAF1BRAF | |
| SCHEMBL1336154 | 0.85 | PTGES (0.47) | PTGESCYP2D6 | |
| SCHEMBL13393760 | 0.84 | PTGES (0.42) | PTGESHDAC6RAF1BRAFALDH1A1 | |
| SCHEMBL1337303 | 0.84 | PTGES (0.49) | PTGESHDAC6RAF1BRAF | |
| SCHEMBL1338460 | 0.82 | PTGES (0.54) | PTGESCYP2D6 | |
| SCHEMBL12130168 | 0.82 | PTGES (0.53) | PTGESCYP2D6RAF1BRAF | |
| SCHEMBL1336164 | 0.80 | PTGES (0.58) | PTGESCYP2D6 | |
| SCHEMBL1337761 | 0.80 | PTGES (0.66) | PTGESCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275656-A1 | 3H-Imidazo [4, 5-C] Pyridine- 6 -Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275656-A1 | 3H-Imidazo [4, 5-C] Pyridine- 6 -Carboxamides As Anti-Inflammatory Agents | MAP4, IL4, MAP7D3 | PTGES 151/4885CYP2D6 585/4885HDAC6 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.